{
    "article_link": "https://doi.org/10.1038/s41467-020-18546-x",
    "data": [
        {
            "id": "data_1",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120575",
            "format": "scRNA-seq",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE120575"
        },
        {
            "id": "data_2",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115978",
            "format": "scRNA-seq",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE115978"
        },
        {
            "id": "data_3",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123813",
            "format": "scRNA-seq",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE123813"
        },
        {
            "id": "data_4",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78220",
            "format": "Bulk RNA-seq",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE78220"
        },
        {
            "id": "data_5",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE91061",
            "format": "Bulk RNA-seq",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE91061"
        },
        {
            "id": "data_6",
            "omics": "Transcriptomics",
            "link": "https://www.ebi.ac.uk/ena/data/view/PRJEB23709",
            "format": "Bulk RNA-seq",
            "source": "European Nucleotide Archive (ENA)",
            "public_id": "PRJEB23709"
        },
        {
            "id": "data_7",
            "omics": "Transcriptomics",
            "link": "https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000452.v3.p1",
            "format": "Bulk RNA-seq",
            "source": "dbGaP",
            "public_id": "phs000452.v3.p1"
        }
    ],
    "analyses": [
        {
            "id": "analysis_1",
            "analysis_name": "Single cell cluster",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "ICT_outcome": [
                    "Responder",
                    "Non-Responder"
                ]
            }
        },
        {
            "id": "analysis_2",
            "analysis_name": "Differential analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "cell_cluster": [
                    "TREM2hi macrophages",
                    "Tgd_c21 γδ T cells",
                    "B_c22 B cells",
                    "Immunoregulatory related Mϕ"
                ]
            }
        },
        {
            "id": "analysis_3",
            "analysis_name": "Pathway analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "cell_cluster": [
                    "TREM2hi macrophages",
                    "Inflammatory Mϕ",
                    "Immunoregulatory related Mϕ"
                ]
            }
        },
        {
            "id": "analysis_4",
            "analysis_name": "Classification analysis",
            "analysis_data": [
                "data_4",
                "data_1"
            ],
            "label": {
                "ICT_outcome": [
                    "Responder",
                    "Non-Responder"
                ]
            }
        },
        {
            "id": "analysis_5",
            "analysis_name": "Validation analysis",
            "analysis_data": [
                "data_4",
                "data_5",
                "data_6",
                "data_7"
            ],
            "label": {
                "ICT_outcome": [
                    "Responder",
                    "Non-Responder"
                ],
                "treatment_scheme": [
                    "anti-PD-1",
                    "anti-PD-1/anti-CTLA-4"
                ]
            }
        },
        {
            "id": "analysis_6",
            "analysis_name": "Comparison analysis",
            "analysis_data": [
                "data_4",
                "data_5",
                "data_6",
                "data_7"
            ],
            "label": {
                "signature": [
                    "IMPRES.Sig",
                    "IRG.Sig",
                    "IPRES.Sig",
                    "T.cell.inflamed.Sig",
                    "LRRC15.CAF.Sig",
                    "EMT.Sig",
                    "Inflammatory.Sig",
                    "Blood.Sig",
                    "IFNG.Sig",
                    "CD8.Sig",
                    "PDL1.Sig",
                    "CRMA.Sig"
                ]
            }
        },
        {
            "id": "analysis_7",
            "analysis_name": "Stratified analysis",
            "analysis_data": [
                "data_6"
            ],
            "label": {
                "treatment_scheme": [
                    "anti-PD-1",
                    "anti-PD-1/anti-CTLA-4"
                ],
                "sample_collection_time": [
                    "before ICT",
                    "after ICT"
                ]
            }
        },
        {
            "id": "analysis_8",
            "analysis_name": "Pathway analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "cell_cluster": [
                    "Tgd_c21 γδ T cells"
                ],
                "ICT_outcome": [
                    "Responder",
                    "Non-Responder"
                ]
            }
        },
        {
            "id": "analysis_9",
            "analysis_name": "Pathway analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "cell_cluster": [
                    "B_c22 B cells"
                ],
                "ICT_outcome": [
                    "Responder",
                    "Non-Responder"
                ]
            }
        }
    ],
    "results": [
        {
            "analysis_id": "analysis_1",
            "metrics": "Percentage change",
            "value": "TREM2hi macrophages increased 15.1-fold in non-responders; Tgd_c21 γδ T cells increased 12.1-fold; B_c22 B cells decreased 9.3-fold in non-responders.",
            "features": [
                "TREM2hi macrophages",
                "Tgd_c21 γδ T cells",
                "B_c22 B cells"
            ]
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Fold change",
            "value": "15.1-fold increase in TREM2hi macrophages in non-responders",
            "features": [
                "TREM2",
                "SPP1",
                "RNASE1",
                "MT1G",
                "SEPP1",
                "FOLR2",
                "NUPR1",
                "KLHDC8B",
                "CCL18",
                "MMP12",
                "APOC2",
                "C3",
                "C1QA",
                "C1QB",
                "C1QC"
            ]
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Fold change",
            "value": "12.1-fold increase in Tgd_c21 γδ T cells in non-responders",
            "features": [
                "RRM2",
                "BIRC5",
                "SPC24",
                "UBE2C",
                "CDCA5"
            ]
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Fold change",
            "value": "9.3-fold decrease in B_c22 B cells in non-responders",
            "features": [
                "ABCA6",
                "LEF1",
                "FGR",
                "IL2RA",
                "ITGAX",
                "IL7"
            ]
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Fold change",
            "value": "2.1-fold increase in Immunoregulatory related Mϕ in responders",
            "features": [
                "LCK",
                "TIGIT",
                "PTPRCAP",
                "KLRK1",
                "LAT",
                "IL32",
                "IFITM1",
                "CCL5"
            ]
        },
        {
            "analysis_id": "analysis_3",
            "metrics": "Pathway enrichment",
            "value": "TREM2hi macrophages enriched in complement cascade and M2 polarization pathways",
            "features": [
                "C1QA",
                "C1QB",
                "C1QC",
                "C3",
                "CD276",
                "FN1",
                "MRC1",
                "CCL13",
                "CCL18",
                "LYVE1",
                "PDCD1LG2",
                "TGFB2",
                "ARG2"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "AUC",
            "value": "0.98 (95% CI: 0.96–1)",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "Sensitivity",
            "value": "93% (95% CI: 72–100%)",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "Specificity",
            "value": "85% (95% CI: 59–97%)",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "AUC",
            "value": "0.96 (95% CI: 0.94–0.99) in GSE91061; 0.86 (95% CI: 0.82–0.91) in PRJEB23709; 0.88 (95% CI: 0.84–0.91) in MGSP",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Sensitivity",
            "value": "88% (95% CI: 72–97%) in GSE91061; 78% (95% CI: 61–90%) in PRJEB23709; 79% (95% CI: 68–87%) in MGSP",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Specificity",
            "value": "92% (95% CI: 78–99%) in GSE91061; 78% (95% CI: 66–88%) in PRJEB23709; 79% (95% CI: 67–88%) in MGSP",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Validation in BCC",
            "value": "TREM2hi macrophage signature decreased in post-anti-PD-1 responsive BCC tumors; B_c22 B cell signature increased in post-anti-PD-1 responsive BCC tumors",
            "features": [
                "TREM2hi macrophages",
                "B_c22 B cells"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Signature composition",
            "value": "40-gene TREM2hi macrophage signature (e.g., C1QA, C1QB, C1QC, PD-L2)",
            "features": [
                "TREM2hi macrophages"
            ]
        },
        {
            "analysis_id": "analysis_6",
            "metrics": "Ranking",
            "value": "ImmuneCells.Sig ranked first in GSE78220, third in GSE91061, second in PRJEB23709 and MGSP",
            "features": [
                "ImmuneCells.Sig"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "Percentage change",
            "value": "Tgd_c21 γδ T cells significantly increased in anti-PD-1 non-responders",
            "features": [
                "Tgd_c21"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "Percentage change",
            "value": "B_c22 B cells significantly decreased in anti-PD-1 non-responders",
            "features": [
                "B_c22"
            ]
        },
        {
            "analysis_id": "analysis_8",
            "metrics": "Pathway enrichment",
            "value": "Tgd_c21 γδ T cells show reduced IFNγ signaling and increased oncogenic pathways",
            "features": [
                "HALLMARK_E2F_TARGETS",
                "HALLMARK_MITOTIC_SPINDLE",
                "HALLMARK_MYC_TARGETS_V1",
                "IFNγ signaling",
                "Ca2+ mobilization",
                "NF-kappaB activation",
                "immunoregulatory interactions"
            ]
        },
        {
            "analysis_id": "analysis_9",
            "metrics": "Pathway enrichment",
            "value": "B_c22 B cells show reduced oncogenic signaling (Toll receptor, NOTCH1, MAPK, MYC)",
            "features": [
                "Toll receptor signaling",
                "NOTCH1",
                "MAPK",
                "MYC"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "Z-score threshold",
            "value": "Z-score <0.1 indicates non-response to combo therapy; Z-score [0.1, 0.19] indicates possible response to combo therapy; Z-score >0.19 indicates response to anti-PD-1 therapy",
            "features": [
                "ImmuneCells.Sig"
            ]
        }
    ]
}